SK Bioscience Publishes "2025 ESG Report"

Integration and Consolidation of Subsidiaries' ESG Information

SK Bioscience is establishing an integrated ESG (Environmental, Social, and Governance) management system that includes its overseas subsidiaries.

SK Bioscience ESG Website. SK Bioscience

On July 22, SK Bioscience announced that it has published its "2025 ESG Report" on its website, which consolidates and connects ESG information from its subsidiaries, including IDT Biologika, a German CDMO specialist acquired last year.

In this report, SK Bioscience systematically integrates details on sustainable management practices, strategies, performance by area, and data from the past year, including its subsidiaries. In particular, the company reflected domestic and international ESG disclosure trends by applying the "European Sustainability Reporting Standards (ESRS)" double materiality assessment guidelines, distinguishing key topics from both social impact and financial perspectives. Additionally, for the first time, the company introduced the IRO (Impact, Risk, Opportunity) assessment, which analyzes the degree of impact that sustainability topics have on the environment, society, and the company itself.

The key topics for environmental and social impact were identified as: securing and developing talent and specialized personnel; strengthening product safety and quality; expanding access to pharmaceuticals; managing hazardous chemicals and pollutants; and implementing ethical and compliant management. For financial materiality, the three key topics selected were: governance; strategy; and risk management. The response strategies and major achievements for each topic were systematically disclosed in connection with business activities.

In particular, to fulfill its responsibilities as a global vaccine company, information related to "access to pharmaceuticals" has been significantly enhanced. By providing detailed disclosures on activities such as expanding global vaccine supply strategies, efforts to improve price accessibility, and distributing vaccines to low- and middle-income countries, SK Bioscience has clearly demonstrated its commitment to fulfilling its corporate social responsibilities.

SK Bioscience manages risks and opportunities across the environment, society, and governance in an integrated manner, centering on its board-level ESG Committee. The company systematically implements area-specific tasks through its ESG working group and dedicated ESG organization, thereby creating sustainable corporate value.

In the environmental sector, the company is promoting environmental management, greenhouse gas reduction, and strengthening its environmental impact management system. In the social sector, it is focusing on enhancing employee well-being, advancing human rights management, managing a sustainable supply chain, contributing to local communities, and establishing a culture of safety and health. In the governance sector, SK Bioscience is strengthening transparency and responsible management through the operation of an independent and professional board of directors, ethical management, and the advancement of its internal control system.

In recognition of these ESG management achievements, SK Bioscience received an "A" rating for the third consecutive year in the integrated ESG rating by the Korea Institute of Corporate Governance and Sustainability (KCGS) last year, and also received an "A" rating for the second consecutive year in the MSCI ESG assessment, earning high trust from major institutions.

Park Jongsu, Head of the Sustainability Management Division at SK Bioscience, stated, "This report enhances transparency based on consolidated disclosures in accordance with international standards," and added, "We will continue to meet the global community’s sustainability demands and fulfill our responsibilities and roles as a global company."

This content was produced with the assistance of AI translation services.